Cdk inhibitor BAI

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 130189

CAS#: N/A

Description: Cdk inhibitor BAI is a cancer therapeutic agent with anti-proliferative effects that plays a key role in FTI-mediated apoptosis in human renal carcinoma cells, as well as the treatment of head and neck cancers. For the treatment of renal carcinoma, by synergizing with FTI, BAI activates DEVDase, cleaves PARP, and leads to the degradation of anti-apoptotic proteins in Caki cells. BAI was also found to inhibit the expression of ICAM-1 and VCAM-1 which in turn leads to the inhibition of cell adhesion, in part due to the down-regulation of the activity of NF-κB.

Chemical Structure

img
Cdk inhibitor BAI
CAS# N/A
Instruction

Theoretical Analysis

MedKoo Cat#: 130189
Name: Cdk inhibitor BAI
CAS#: N/A
Chemical Formula: C24H22N4O3S
Exact Mass: 446.14
Molecular Weight: 446.530
Elemental Analysis: C, 64.56; H, 4.97; N, 12.55; O, 10.75; S, 7.18

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Cdk inhibitor BAI

IUPAC/Chemical Name: 2-([1,1'-biphenyl]-4-yl)-N-(5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl)acetamide

InChi Key: ACNJMIYZGUUYIE-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H22N4O3S/c29-23(15-17-7-9-19(10-8-17)18-5-2-1-3-6-18)25-24-21-16-20(11-12-22(21)26-27-24)28-13-4-14-32(28,30)31/h1-3,5-12,16H,4,13-15H2,(H2,25,26,27,29)

SMILES Code: O=C(NC1=NNC2=C1C=C(N(CCC3)S3(=O)=O)C=C2)CC4=CC=C(C5=CC=CC=C5)C=C4

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 446.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1. Jang JH, Cho YC, Kim KH, Lee KS, Lee J, Kim DE, Park JS, Jang BC, Kim S, Kwon TK, Park JW. BAI, a novel Cdk inhibitor, enhances farnesyltransferase inhibitor LB42708-mediated apoptosis in renal carcinoma cells through the downregulation of Bcl-2 and c-FLIP (L). Int J Oncol. 2014 Oct;45(4):1680-90. doi: 10.3892/ijo.2014.2534. Epub 2014 Jul 4. PMID: 24993441.

2. Shin HC, Song DW, Baek WK, Lee SR, Kwon TK, Lee J, Park SH, Jang BC, Park JW. Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor. Chemotherapy. 2009;55(5):353-62. doi: 10.1159/000232450. Epub 2009 Aug 5. PMID: 19657189.

3. Oh JH, Park EJ, Park JW, Lee J, Lee SH, Kwon TK. A novel cyclin-dependent kinase inhibitor down-regulates tumor necrosis factor-alpha (TNF-alpha)-induced expression of cell adhesion molecules by inhibition of NF-kappaB activation in human pulmonary epithelial cells. Int Immunopharmacol. 2010 May;10(5):572-9. doi: 10.1016/j.intimp.2010.02.004. Epub 2010 Feb 13. PMID: 20156602.